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INTRODUCTION
Breast cancer is the most common fatal cancer in Korean 
women [1]. The recurrence rate of breast cancer is relatively 
high, at 20-30%, depending on stage, despite its relatively high 
5-year survival rate [2]. Therefore, it is important to predict 
the risk of recurrence and administer adjuvant chemotherapy 
to high risk patients. 
Adjuvant systemic treatment decreases the risk of develop-
ing distant metastases and death by about 30% in patients with 
node-negative breast cancer, but 70% of patients with node 
negative breast cancer will experience toxicity without benefit 
from such treatment [3,4]. Despite this observation, most of 
these patients are still considered candidates for chemothera-
py. Several commonly used guidelines have been developed 
based on clinicopathological factors: lymph-node status, age, 
tumor size, histological grade, and estrogen receptor (ER) sta-
tus. However, these factors do not accurately predict the exact 
clinical outcomes. In Korea, patients with node-negative breast 
cancer comprise about 65% of all patients with breast cancer 
[5]. Therefore, new prognostic markers are needed to reduce 
overtreatment with its unnecessary exposure to toxicity. One 
of the new prognostic markers is the 70-gene prognostic sig-
nature (MammaPrint
TM; Agendia, Amsterdam, Netherlands). 
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Purpose: A 70-gene prognostic signature has prognostic value in 
patients with node-negative breast cancer in Europe. This diag-
nostic test known as “MammaPrint
TM (70-gene prognostic sig-
nature)” was recently validated and implementation was feasible. 
Therefore, we assessed the 70-gene prognostic signature in   
Korean patients with breast cancer. We compared the risk pre-
dicted by the 70-gene prognostic signature with commonly used 
clinicopathological guidelines among Korean patients with breast 
cancer. We also analyzed the 70-gene prognostic signature and 
clinicopathological feature of the patients in comparison with a 
previous validation study. Methods: Forty-eight eligible patients 
with breast cancer (clinical T1-2N0M0) were selected from four 
hospitals in Korea. Fresh tumor samples were analyzed with a 
customized microarray for the 70-gene prognostic signature. 
Concordance between the risk predicted by the 70-gene prog-
nostic signature and risk predicted by commonly used clinico-
pathological guidelines (St. Gallen guidelines, National Institutes 
of Health [NIH] guideline, and Adjuvant! Online) was evaluated. 
Results: Prognosis signatures were assessed in 36 patients. No 
significant differences were observed in the clinicopathological 
features of patients compared with previous studies. The 70-gene 
prognosis signature identified five (13.9%) patients with a low-risk 
prognosis signature and 31 (86.1%) patients with a high-risk prog-
nosis signature. Clinical risk was concordant with the prognosis 
signature for 29 patients (80.6%) according to the St. Gallen guide-
lines; 30 patients (83.4%) according to the NIH guidelines; and 23 
patients (63.8%) according to the Adjuvant! Online. Our results 
were different from previous validation studies in Europe with about 
a 40% low-risk prognosis and about a 60% high-risk prognosis. 
The high incidence in the high-risk group was consistent with data 
in Japan. Conclusion: The results of 70-gene prognostic signature 
of Korean patients with breast cancer were somewhat different 
from those identified in Europe. This difference should be studied 
as whether there is a gene disparity between Asians and Europe-
ans. Further large-scale studies with a follow-up evaluation are 
required to assess whether the use of the 70-gene prognostic sig-
nature can predict the prognosis of Korean patients with breast 
cancer. 
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Analysis of gene expression patterns has led to the discovery 
of this prognostic gene signature [6]. The 70-gene prognostic 
signature has been validated in a number of European patient 
series [7-10]. But, there is only one Japanese study [11] about 
a 70-gene prognostic signature in Asians and no Korean pa-
tients with breast cancer. Thus, our study is the first about the 
70-gene prognostic signature in Korea.
We assessed the 70-gene prognostic signature in Korean pa-
tients with breast cancer. We compared the risks predicted by 
the 70-gene prognostic signature with commonly used clini-
copathological guidelines among Korean patients with breast 
cancer. We also analyzed the 70-gene prognostic signature and 
clinicopathological features of patients compared with a pre-
vious validation study.
METHODS
Patients
This study was conducted using tumor samples and clinical 
data from 48 patients at four different hospitals in Korea: Ajou 
University Hospital, Suwon; Samsung Medical Center, Seoul; 
Asan Medical Center, Seoul; and Ewha Womans’ University 
Mokdong Hospital, Seoul. The patients were selected according 
to the following criteria: they were diagnosed between March 
2008 and September 2009, they had a clinically unilateral T1 
or T2 (tumor size ≤5 cm) tumor that was node-negative, and 
they had not received neoadjuvant therapy. Patients with pre-
vious malignancies or with bilateral synchronous breast tumors 
were excluded. All patients were told about the 70-gene prog-
nostic signature and voluntarily agreed to take the test. This 
retrospective study was approved by principal investigator’s 
institutional review board (Accept No. AJIRB-MED-MDB-10- 
228). Memorandum of Understanding was concluded between 
other institutions. The clinicopathological data were collected 
from the medical records, histologic tumor grading was de-
fined according to Elston and Ellis [12]. The ER and proges-
terone receptor (PR) status were determined by immunohis-
tochemistry, which was interpreted as positive if more than 
10% of the tumor cell nuclei stained positive. The erb-B2 re-
ceptor status was assessed by the intensity of the membrane 
staining using immunohistochemistry and fluorescent in situ 
hybridization. Tumors with a score of 3+ (strong homogeneous 
staining) were considered HER2-positive. In case of 2+ scores 
(moderate homogeneous staining) fluorescent in situ hybrid-
ization (FISH) was used to determine amplification [13]. 
Tumor samples 
Because collecting tumor tissue from surgical specimens is 
not a standard procedure, patient permission and informed 
consents were obtained before surgery. Within 1 hour after 
surgery, a tumor sample was taken for a quality control check 
of the RNA. For this purpose, a punch biopsy device was used 
to obtain a tumor sample with a minimum thickness of 3 mm 
and a maximum thickness of 5 mm. The samples were stored 
in a container with RNA stabilizing solution (such as RNARe-
tain; Asuragen, Austin, USA) directly after their removal, and 
the samples were sent to Agendia’s laboratories for RNA extrac-
tion and microarray analysis, as previously described [6]. Sam-
ples were available for RNA extraction if they contained at least 
30% tumor cells on the hematoxylin-eosin stained sections. 
Useful RNA could be extracted for hybridization and analysis 
from 75.0% of the tumor samples, so 38 samples were available 
for the analysis. Ten samples were rejected based on having 
less than 30% invasive tumor cells in the samples or an insuf-
ficient quality of tumor RNA.
Gene expression analysis
To assess the mRNA expression level of the 70 genes, the RNA 
was hybridized to a custom-designed array (MammaPrint
TM, 
FDA 510(k) cleared) at Agendia Laboratories, and the person-
nel were ‘blinded’ to the clinical data. The tumors were classi-
fied only according to a dichotomized value: a low-risk prog-
nostic signature or a high-risk prognostic signature. A tumor 
was defined as having a low-risk prognostic signature if the 
Pearson’s correlation coefficient for the expression of the 70-
gene prognostic signature in that tumor with the previously 
established classifier was greater than 0.4, which is the cut-off 
point we used, as described previously [6,7,10,14]. The previ-
ously established classifier defined a good prognosis, as a more 
than 90% probability for 5-year distant metastasis-free survival 
for node-negative patients [6].
Clinical risk classification
According to the St. Gallen guideline, a low clinical risk was 
defined as possessing all of the following criteria: an ER posi-
tive or/and PR positive status, a tumor size of 2 cm or less, 
histological grade 1, and an age of 35-year or above [15]. The 
National Institutes of Health (NIH) guideline recommends 
that the low-risk group in the node negative group had a tumor 
size smaller than 1 cm and a favorable histological subtype such 
as tubular and mucinous cancer [16,17].
The Adjuvant! Online software version 8.0 (www.adjuvan-
tonline.com) calculates the 10-year survival probability based 
on patient age, tumor size and grade, ER-status, nodal status, 
and co-morbidities [18,19]. The low-clinical risk group for this 
calculation was defined as patients with 10-year overall survival 
probabilities of at least 88% in ER-positive tumors and of at 
least 92% if ER expression was seen in ER-negative tumors [20].The70-GenePrognosticSignatureinBreastCancer 35
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Statistical analysis
Analysis was performed using SPSS version 15.0 (SPSS Inc., 
Chicago, USA). The p-value was two-sided. Differences be-
tween the groups of interest were tested with the Pearson χ2 
test or the Fisher’s exact test. A p-value <0.05 was considered 
significant. 
RESULTS 
Of the 48 eligible patients, 12 were excluded because of sam-
pling failure (n=10) or lymph node metastasis on permanent 
pathological findings (n=2). A prognostic signature was ob-
tained for the remaining 36 patients. 
Five of the 36 (13.9%) patients had a low risk prognostic sig-
nature and 31 (86.1%) patients had a high-risk prognostic sig-
nature. The mean age of the eligible patients was 47 years (me-
dian, 45; range, 23-68), and the mean tumor diameter was 2.0 
cm (median, 1.8; range, 0.3-5.1). No significant difference in 
age, operative method, tumor size, ER status, the PR status, 
lymphovascular invasion, and erb-B2 receptor status between 
the low-risk prognostic signature group and the high-risk prog-
nostic signature group was observed. Only histological grade 
was significantly different between the low and high-risk prog-
nostic signature groups (p=0.045). A low-risk signature was 
not found for tumors with lympovascular invasion, for erb-B2 
receptor positivity, and those with a poor histological grade. 
The median tumor diameter was 1.9 cm (range, 0.3-4.5 cm) in 
the high-risk group and 1.6 cm (range, 0.5-5.1 cm) in the low-
risk group (Table 1). 
According to the St. Gallen criteria, 30 of 36 (83.3%) patients 
were at a high-risk, according to the NIH guideline, 31 of 36 
(86.1%) patients were at a high-risk, and according to the Ad-
juvant! Online, 22 of 36 (61.2%) patients were at a high-risk. 
The clinical risk for seven patients (19.4%), six patients (16.6%) 
and 13 patients (36.2%) was discordant with using the prog-
nostic signature according to the St. Gallen criteria, the NIH 
guideline and Adjuvant! Online, respectively (Table 2).
We compared our results with those of previous validation 
studies[7,8,10,13,21]. Table 3 shows the clinicopathological 
characteristics and results of the 70-gene prognostic signature 
derived from previously published studies. Except for patient 
age in one validation study and 70-gene prognostic signature 
results, the cinicopathological factors of patients were not sig-
nificantly different between previous studies and our study. 
The previous published studies in Europe, but not the data 
released in Japan, showed a similar pattern. In the European 
studies, 36.8-52% of the patients were classified in a low-risk 
group, and 49-63.2% were in the high-risk group. In a study 
published in Japan, 19.6% of the patients were in the low-risk 
group and 80.4% were in the high-risk group.
Table 1. Characteristics of the patients and their tumor for the analysis 
of the 70-gene prognostic signature 
70-gene prognosis signature 
(n=36)
p-value
Low-risk  
(n=5, 13.3%)
High-risk  
(n=31, 86.1%)
Age (yr) 
   <40 
   40-49 
   ≥50 
 
0
  5 (100)
0
 
2 (6.4)
19 (61.3)
10 (32.3)
0.477
Type of surgery 
   Breast conserving surgery 
   Mastectomy 
 
  5 (100)
0
 
28 (90.3)
3 (9.7)
0.630
Tumor size (cm)
   ≤2
   >2 
 
3 (60)
2 (40)
 
20 (64.5)
11 (35.5)
NS
Histologic grade 
   I 
   II
   III
 
3 (60)
2 (40)
0
 
  4 (12.9)
15 (48.4)
12 (38.7)
0.045
Estrogen receptor status 
   Negative 
   Positive 
 
1 (20)
4 (80)
 
  6 (19.4)
25 (80.6)
NS
Progesterone receptor status 
   Negative 
   Positive 
 
1 (20)
4 (80)
 
10 (32.3)
21 (67.7)
0.664
Lymphovascular invasion 
   Negative 
   Positive 
  5 (100)
0
 
26 (83.9)
  5 (16.1)
NS
Erb-B2 receptor status 
   Negative 
   Positive 
 
4 (80)
1 (20)
 
24 (77.4)
  7 (22.6)
NS
NS=not significant.
Data are presented as number (%). 
Table 2. Concordances between the 70-gene prognostic signature and 
the risk assessment according to the other clinicopathological risk in-
dexes 
70-gene prognosis signature 
(n=36) Discordant 
finding Low-risk  
(n=5, 13.3%)
High-risk 
(n=31, 86.1%)
St. Gallen criteria 
   Low (n=6) 
   High (n=30) 
  
 2* (5.6)
  3 (8.3)
  
    4 (11.1)
27* (75)
  
  7 (19.4)
NIH guideline 
   Low (n=5) 
   High (n=31) 
 
 2* (5.6)
3 (8.3)
 
  3 (8.3)
   28* (77.8)
 
  6 (16.6)
Adjuvant! Online 
   Low (n=14) 
   High (n=22) 
 
 3* (8.3) 
2 (5.6)
 
  11 (30.6)
   20* (55.6)
 
13 (36.2)
NIH=National Institute of Health.
Data are presented as number (%).
*These values were summed to obtain concordant findings.36  KukYoungNa,etal.
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DISCUSSION
A 70-gene prognostic signature was identified by perform-
ing gene expression profiling on 78 patients with breast cancer 
at the Netherlands Cancer Institute [6]. Subsequently, the 70-
gene signature was then applied to a large test set of 295 pa-
tients with breast cancer from the same institution, and the 
results confirmed that the signature could classify patients ac-
cording to 10-years survival outcome [10]. This signature has 
been validated in many studies as a more powerful prognostic 
factor for distant metastasis and death than the current clini-
copathological factors. These studies verified the molecularly 
identified patients with biologically less aggravated cancer [7, 
8,13,21]. Many recent studies have shown that this signature 
can be used to classify postmenopausal women (older age 
women), neoadjuvant chemotherapy patients and node-posi-
tive patients [9,22,23]. 
We studied the 70-gene prognostic signature in Korean pa-
tients with breast cancer who had a median age of 45-years 
with node-negative, clinical T1-T2 breast cancer. The 70-gene 
prognostic signature displayed a remarkably high-risk group 
in our patients (13.9% of the low-risk group, 86.1% of the high-
risk group). No significant differences in age, tumor size, and 
ER status between the low-risk group and the high-risk group 
were found. Only histological grade was significantly different 
between the low and high-risk prognostic signature groups. 
In our report, the proportion of tumors with a low-risk prog-
nosis signature was 13.9%, which is less than the percentage 
(36.8-52%) reported in previous validation studies in Europe 
[8,10,13,21]. Yet the results released in Japan (19.6%) are simi-
lar to our results for the high-risk group [11]. No significant dif-
ferences in tumor size, histological grade, and the ER status be-
tween our patients and the patients of the previous validation 
studies in Europe were found. Except for one validation study 
[10], patient age also was not significantly different. Neverthe-
less, our results are different from the previous validation stud-
ies in Europe showing that about 40% of the European patients 
had a low-risk prognosis and about 60% had a high-risk prog-
nosis. In Europe, incidence rate of breast increase with age and 
the highest rates occur in the oldest age group but incidence rate 
of breast cancer in Korea is the highest in the 40s [1,5,24]. Fur-
thermore, 70-gene prognostic signature is a prediction model 
developed by extracting candidate genes in 5,000 genes from 
Europeans [6]. So the causes for difference between our results 
and those of European data need further study, but we think that 
racial differences had some effects on the study cohort differences. 
The clinical utility of the 70-gene prognostic signature de-
pends on its potential value in addition to using traditional 
prognostic factors. Therefore, we compared the signature’s risk 
assessment to the clinicopathological risk assessment using 
the St. Gallen criteria, the NIH guidelines, and Adjuvant! On-
line. Overall, as compared with that of the clinicopathological 
risk guidelines, about one fifth of the patients were discordant 
with the 70-gene prognostic signature. (Discordance of 19.4% 
compared to the St. Gallen criteria, 16.6% compared to the 
NIH guideline, and 36.2% compared to Adjuvant! Online) In 
a previous study, the discordant rate between the 70-gene prog-
nostic signature and other clinicopathological guidelines was 
Table 3. Comparison of the clinicopathologic features of the previous validation studies 
Present data 
(n=36)  
van de Vijver et al. [10] 
(n=295)
*Bueno-de-Mesquita 
et al. [8] (n=123)
Bueno-de-Mesquita 
et al. [21] (n=427)
†Ishitobi et al. [11] 
(n=102)
No. (%) No. (%) p-value No. (%) p-value No. (%) p-value No. (%) p-value
Age (yr)
   <40
   40-49
   ≥50
 
2 (5.5)
24 (66.7)
10 (27.8)
 
63 (19.5)
183 (64.5)
49 (16.5)
0.039  
22 (18)
61 (49)
40 (33)
0.104 
67 (15.7)
225 (52.7)
135 (31.6)
0.172
34 (33.3)
68 (66.7)
Tumor size (cm)  
   ≤2
   >2
 
23 (63.9)
13 (36.1)
 
155 (52.5)
140 (47.5)
0.219  
76 (62)
47 (38)
0.848  
301 (70.5)
126 (29.5)
0.450  
49 (49.0)
51 (51.0)
0.122
Histologic grade
   I
   II
   III
 
  7 (19.4)
17 (47.3)
12 (33.3)
 
75 (25.4)
101 (34.2)
119 (40.3)
0.306  
20 (16)
53 (43)
50 (41)
0.745  
87 (20.4)
204 (47.8)
136 (31.9)
1.000  
20 (19.8)
29 (28.7)
52 (51.5)
0.095
Estrogen receptor status
   Negative         
   Positive
 
  7 (19.4)
29 (80.6)
 
69 (23.4)
226 (76.6)
0.679  
29 (24)
94 (76)
0.659  
85 (19.9)
342 (80.1)
0.983  
39 (42.9)
52 (57.1)
0.063
70-gene prognostic signature
   Low-risk
   High-risk
  
  5 (13.9)
31 (86.1)
  
115 (40)
180 (60)
0.03  
64 (52)
59 (48)
<0.01  
219 (51)
208 (49)
0.01  
20 (19.6)
82 (80.4)
0.616
*This study classified age according to <40, 41-50, 51-60; 
†This study classified of age according to <50, ≥50. The70-GenePrognosticSignatureinBreastCancer 37
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28.3-39% [7,19]. A discordant rate is not mentioned in many 
of the previous validation studies, and a comparison between 
the 70-gene prognostic signature and the clinicopathological 
guidelines indicates that this signature is a more powerful pre-
dictor of disease outcome than the currently used clinicopath-
ological guidelines [7,9,10,19]. Therefore, these discordant rates 
indicate that using this signature could result in a substantial 
reduction of the number of patients who would be recommend-
ed for chemotherapy. But, our results of a low incidence for the 
low-risk group indicate that there are fewer Korean patients 
that would benefit from this prognostic signature than those 
in Europe. Moreover, because our study did not assess the over-
all survival rate and recurrence rate, it is unclear whether the 
70-gene prognostic signature is purely prognostic or predictive 
for treating this group in Korea. 
This study had several limitations. First, our sample size was 
relatively small, suggesting that a larger study may be able to 
define whether or not the 70-gene prognostic signature can 
identify patients with node negative breast cancer and who 
have an excellent disease outcome in Korea. Second, no as-
sessment was made after the follow-up period (this is a pre-
liminary report involving patients who were diagnosed within 
1 year), and a follow-up evaluation may be required to deter-
mine whether the 70-gene prognostic signature has prognostic 
value compared with the clinicopathological guidelines. If fur-
ther prospective randomized trials confirm the prognostic and 
predictive values of the 70-gene prognostic signature in Korea 
as compared with that for the conventional clinicopathologi-
cal guidelines, then this signature may become a powerful prog-
nostic tool for Korean patients with breast cancer to adminis-
ter chemotherapy to properly selected patients. 
The results of the 70-gene prognostic signature of Korean 
patients with breast cancer were different from those from 
Europe. These differences should be studied as to whether the 
gene disparity between Asians and Europeans influenced the 
results. Further large-scale studies with a follow-up evaluation 
are required to assess whether the use of the 70-gene prognos-
tic signature can predict a prognosis for Korean patients with 
breast cancer. 
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